Venturi Wealth Management LLC Sells 559 Shares of Amgen Inc. $AMGN

Venturi Wealth Management LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,449 shares of the medical research company’s stock after selling 559 shares during the quarter. Venturi Wealth Management LLC’s holdings in Amgen were worth $3,197,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. DMC Group LLC raised its position in Amgen by 1.2% in the 2nd quarter. DMC Group LLC now owns 3,669 shares of the medical research company’s stock valued at $1,024,000 after purchasing an additional 44 shares during the last quarter. BankPlus Trust Department raised its position in Amgen by 41.6% in the 2nd quarter. BankPlus Trust Department now owns 11,663 shares of the medical research company’s stock valued at $3,256,000 after purchasing an additional 3,425 shares during the last quarter. Independent Solutions Wealth Management LLC raised its position in shares of Amgen by 3.9% during the second quarter. Independent Solutions Wealth Management LLC now owns 9,335 shares of the medical research company’s stock worth $2,606,000 after acquiring an additional 348 shares during the last quarter. Shell Asset Management Co. lifted its stake in shares of Amgen by 86.2% during the second quarter. Shell Asset Management Co. now owns 16,076 shares of the medical research company’s stock valued at $4,489,000 after acquiring an additional 7,440 shares during the period. Finally, Godsey & Gibb Inc. boosted its holdings in Amgen by 9.9% in the second quarter. Godsey & Gibb Inc. now owns 72,568 shares of the medical research company’s stock valued at $20,262,000 after acquiring an additional 6,565 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the business’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president directly owned 7,209 shares of the company’s stock, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.69% of the company’s stock.

Amgen Trading Up 0.5%

NASDAQ AMGN opened at $295.54 on Wednesday. The stock has a 50-day simple moving average of $287.04 and a 200 day simple moving average of $287.88. The company has a market capitalization of $159.11 billion, a PE ratio of 24.17, a P/E/G ratio of 2.55 and a beta of 0.49. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $335.88.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. The business had revenue of $9.18 billion during the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s payout ratio is presently 77.84%.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Raymond James Financial assumed coverage on Amgen in a report on Wednesday, September 3rd. They set a “market perform” rating for the company. Piper Sandler boosted their price objective on Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a report on Monday, August 25th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Cantor Fitzgerald reissued a “neutral” rating and set a $305.00 price objective on shares of Amgen in a report on Tuesday, June 24th. Finally, UBS Group dropped their price objective on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a report on Wednesday, August 6th. Seven research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $309.42.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.